BioCryst Pharmaceuticals (BCRX) announced the appointment of Dr. Nancy Hutson as chair of its board of directors, effective immediately. Dr. Hutson was appointed to the board in January 2012, bringing over 30 years of experience as a seasoned professional and leader within the pharmaceutical industry. She retired from Pfizer (PFE) in 2006 after spending 25 years in several research and leadership positions, most recently serving as senior vice president of global research & development as well as director of Pfizer’s pharmaceutical R&D site, Groton/New London Laboratories.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BCRX:
- BioCryst Appoints Dr. Nancy Hutson as Chair of the Board
- BioCryst Celebrates Bob Ingram’s Contributions to the Company’s Success
- CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada
- BioCryst says CADTH recommends reimbursement for Orladeyo
- BioCryst reports inducement grants under Nasdaq listing rule